Suchergebnisse - "Remission Induction"

PubPharm (354)

61

Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD : Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD

enthalten in: WHO International Clinical Trials Registry Platform | 2021

62

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

63

Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD : Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD

enthalten in: WHO International Clinical Trials Registry Platform | 2021

64

Remission in axial spondyloarthritis : Developing a consensus definition

enthalten in: Reumatologia clinica | 2021

von Fernández-Carballido, C. | Collantes-Estévez, E. | Gratacós, J. | +2

65

Using a Convolutional Neural Network to Predict Remission of Diabetes After Gastric Bypass Surgery : Machine Learning Study From the Scandinavian Obesity Surgery Register

enthalten in: JMIR medical informatics | 2021

von Cao, Y. | Näslund, I. | Näslund, E. | +3

66

Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease

enthalten in: Clinical and experimental nephrology | 2021

von Tanabe, K. | Samejima, K. | Fukata, F. | +9

67

Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease

enthalten in: Clinical and experimental nephrology | 2021

von Tanabe, K. | Samejima, K. | Fukata, F. | +9

68

Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease

enthalten in: Clinical and experimental nephrology | 2021

von Tanabe, K. | Samejima, K. | Fukata, F. | +9

69

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

70

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021